[Rare disease] Hunterase IV

GC Biopharma is a global bio-tech leader that saves and improves lives, offers a broad range of vaccines, plasma derivatives, therapies for rare diseases, and medicines for chronic diseases

▪Solvent/Detergent treated and Nanofiltered ▪For intravenous use only ▪Plasma from healthy donors  

 ✔ Alyglo : Human Intravenous immunoglobulin 10%
 - U.S. Approval in 2023
 - Successfully launching in 2024

 ✔ I.V.-Globulin SN inj. : Human intravenous Immunoglobulin 5%, 10%
 - A dominant leader of Korea since 1970
 - 611 mil. liters of IVIG distributed worldwide 

▪A 20% solution of human albumin prepared with a cold ethanol fractionation method from plasma from healthy donors

▪High concentrate of human anti-haemophilic factor VIII prepared from pooled plasma of healthy donors

▪Live attenuated varicella vaccine
- WHO-prequalified
- World's 1st Antibiotic-free varicella vaccine

▪Seasonal influenza vaccine
- WHO-prequalified
- Largest flu vaccine supplier to PAHO & UNICEF

▪World's 1st ERT for Neuronopathic MPS II

▪Natural Plant-Based Medicine for the Alleviation of Menopausal Symptoms
▪Red Clover 70% Ethanol Dried Extract Microgranules